Febuxostat improves the local and remote organ changes induced by intestinal ischemia/reperfusion in rats

Digestive Diseases and Sciences

Volumn 58, Issue 3, 2013, Pages 650-659

  Shafik, Amani Nabil ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Allopurinol; Febuxostat; Intestine; Ischemia reperfusion; Liver injury; Lung injury

Indexed keywords

ACETYLCHOLINE; ALANINE AMINOTRANSFERASE; ALLOPURINOL; ASPARTATE AMINOTRANSFERASE; FEBUXOSTAT; MALONALDEHYDE; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; XANTHINE OXIDASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; ILEUM CONTRACTION; INTESTINE ISCHEMIA; INTESTINE MUCOSA; LIVER INJURY; LIVER PROTECTION; LUNG INJURY; LUNG PARENCHYMA; MALE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SMALL INTESTINE; SUPERIOR MESENTERIC ARTERY OBSTRUCTION;

ALANINE TRANSAMINASE; ALLOPURINOL; ANIMALS; ASPARTATE AMINOTRANSFERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GOUT SUPPRESSANTS; INTESTINAL MUCOSA; LIPID PEROXIDATION; LUNG; MALE; MALONDIALDEHYDE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

EID: 84876668065     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2391-1     Document Type: Article

References (54)

1. Tendler DA. Acute intestinal ischemia and infarction. Semin Gastrointest Dis. 2003;14:66-76.
2. Guneli E, Cavdar Z, Islekel H, et al. Erythropoietin protects the intestine against ischemia/reperfusion injury in rats. Mol Med. 2007;13:509-517.
3. Ismail HM, Wenxuan Y, Marc CW, et al. Ischemia-reperfusion injury of the intestine and protective strategies against injury. Dig Dis Sci. 2004;49:1359-1377.
4. Ceppa EP, Fuh KC, Bulkley GB. Mesenteric hemodynamic response to circulatory shock. Curr Opin Crit Care. 2003;9:127-132.
5. Ballabeni V, Barocelli E, Bertoni S, et al. Alterations of intestinal motor responsiveness in a model of mild mesenteric ischemia/reperfusion in rats. Life Sci. 2002;71:2025-2035.
6. Aldemir M, Gürel A, Büyükbayram H, et al. The effects of glucose-insulin-potassium solution and BN 52021 in intestinal ischaemia-reperfusion injury. Vasc Endovascular Surg. 2003;37:345-351.
7. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med. 2002;33:774-797.
8. Julee PS, Deepa RP, Dhrubo JS. Febuxostat: the new generation novel xanthine oxidase Inhibitors. Int Pharm Sci. 2011;1:107-115. http://www. ipharmsciencia.com./Jan-March%202011.html.
9. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk. Nutr Metab Cardiovasc Dis. 2007;17:409-414.
10. Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006;40:2187-2194.
11. Stojadinovic A, Smallridge R, Nath J, et al. Anti-inflammatory effects of U74389F in a rat model of intestinal ischemia/reperfusion injury. Crit Care Med. 1999;27:764-770.
12. Kulah B, Besler HT, Akdag M, et al. The effects of verapamil vs. allopurinol on intestinal ischemia/reperfusion injury in rats. "An experimental study". Hepatogastroenterology. 2004;51:401-407.
13. Terzi C, Kuzu MA, Aşlar AK, et al. Prevention of deleterious effects of reperfusion injury using one-week high-dose allopurinol. Dig Dis Sci. 2001;46:430-437.
14. Margaritis EV, Yanni AE, Agrogiannis G, et al. Effects of oral administration of (l)-arginine, (l)-NAME and allopurinol on intestinal ischemia/reperfusion injury in rats. Life Sci. 2011;6:1070-1076.
15. Sánchez-Lozada LG, Tapia E, Bautista-García P, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294:710-718. http://ajprenal.physiology.org/content/294/4/F710.full.
16. Danielle GS, Vanessa P, Adriana CS, et al. Role of PAF receptors during intestinal ischemia and reperfusion injury. A comparative study between PAF receptor-deficient mice and PAF receptor antagonist treatment. Br J Pharmacol. 2003;139:733-740.
17. Wasowicz W, Neve J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin Chem. 1993;39:2522-2526.
18. Beckman JS, Parks DA, Pearson JD, et al. A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues. Free Radic Biol Med. 1989;6:607-615.
19. Hillegass LM, Griswold DE, Brickson B, et al. Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods. 1990;24:285-295.
20. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
21. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990;186:421-431.
22. Chiu CJ, McArdle AH, Brown R, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg. 1970;101:478-483.
23. Omar R, Nomikos I, Piccorelli G, Savino J, Agarwal N. Prevention of postischaemic lipid peroxidation and liver cell injury by iron chelation. Gut. 1989;30:510-514.
24. Murakami K, Bjertnaes LJ, Schmalstieg FC, et al. A novel animal model of sepsis after acute lung injury in sheep. Crit Care Med. 2002;30:2083-2090.
25. Köksoy C, Kuzu MA, Ergǔn H, et al. Intestinal ischemia-reperfusion impairs vasomotor functions of pulmonary vascular bed. Ann Surg. 2000;231:105-111.
26. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology. 2001;94:1133-1138.
27. Kaplan N, Yagmurdur H, Kilinc K, et al. The protective effects of intravenous anesthetics and verapamil in gut ischemia/reperfusion-induced liver injury. Anesth Analg. 2007;105:1371-1378.
28. Hammerman C, Goldschmidt D, Caplan MS, et al. Amelioration of ischemia-reperfusion injury in rat intestine by pentoxifylline-mediated inhibition of xanthine oxidase. J Pediatr Gastroenterol Nutr. 1999;29:69-74.
29. Cetinkaya A, Bulbuloglu E, Kurutas EB, et al. N-acetylcysteine ameliorates methotrexate-induced oxidative liver damage in rats. Med Sci Monit. 2006;12:274-278. http://www.ncbi.nlm.nih.gov/pubmed/16865059.
30. Granger DN, Stokes KY, Shigematsu T, et al. Splanchnic ischaemia-reperfusion injury: mechanistic insights provided by mutant mice. Acta Physiol Scand. 2001;173:83-91.
31. Lee J, Koo N, Min DB. Reactive oxygen species, aging, and antioxidative nutraceuticals. Compr Rev Food Sci Food Saf. 2004;3:21-33.
32. Okamoto K, Takeshi N. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. J Nippon Med Sch. 2008;75:2-3. http://www.biomedexperts.com/Abstract. bme/18360072/Crystal
33. Anjana P, Mridul C, Himanshu P, et al. Febuxostat - a new treatment for hyperuricaemia in gout - a review article. Natl J Physiol Pharm Pharmacol. 2012;2:23-28. http://njppp.com/.
34. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005;76:1835-1847.
35. Ahmadinejad M, Rex M, Sutton RH, et al. The effects of allopurinol on the ultrastructure of ischaemic and reperfused large intestine of sheep. Aust Vet J. 1996;74:135-139.
36. Devecí E. Role of allopurinol, verapamil, dexamethasone and trifluoperazine as prophylactic agents in intestinal ischemia-reperfusion. Anal Quant Cytol Histol. 2008;30:99-104.
37. Stephanie P, Alexander HT, Roberto A, et al. Allopurinol and xanthine oxidase inhibition in liver ischemia reperfusion. J Hepatobiliary Pancreat Sci. 2011;18:137-146.
38. Guan W, Osanai T, Kamada T, et al. Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol. 2003;41:699-705.
39. Rawan T, James EG. Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clin Geriatr Med. 2010;26:125-147.
40. Liu PG, He SQ, Zhang YH, et al. Protective effects of apocynin and allopurinol on ischemia/reperfusion-induced liver injury in mice. World J Gastroenterol. 2008;14:2832-2837.
41. Taha MO, Simoẽs MJ, Noguerol EC, et al. Effects of allopurinol on ischemia and reperfusion in rabbit livers. Transpl Proc. 2009;41:820-823.
42. Hopson SB, Lust RM, Sun YS, et al. Allopurinol improves myocardial reperfusion injury in a xanthine oxidasefree model. J Natl Med Assoc. 1995;87:480-484.
43. Riaz AA, Wan MX, Schafer T, et al. Allopurinol and superoxide dismutase protect against leucocyte endothelium interactions in a novel model of colonic ischemia-reperfusion. Br J Surg. 2002;89:1572-1580.
44. Vaughan WG, Horton JW, Walker PB. Allopurinol prevents intestinal permeability changes after ischemia-reperfusion injury. J Pediatr Surg. 1992;27:968-972.
45. Riaz AA, Schramm R, Sato T, et al. Oxygen radical-dependent expression of CXC chemokines regulates ischemia/reperfusion-induced leukocyte adhesion in the mouse colon. Free Radic Biol Med. 2003;35:782-789.
46. Hakguder G, Akgur FM, Ates O, et al. Short-term intestinal ischemia-reperfusion alters intestinal motility that can be preserved by xanthine oxidase inhibition. Dig Dis Sci. 2002;47:1279-1283.
47. Malkiel S, Har-el R, Schwalb H, et al. Interaction between allopurinol and copper: possible role in myocardial protection. Free Radic Res Commun. 1993;18:7-15.
48. Kinugasa Y, Ogino K, Furuse Y, et al. Allopurinol improves cardiac dysfunction after ischemia-reperfusion via reduction of oxidative stress in isolated perfused rat hearts. Circ J. 2003;67:781-787.
49. Nishizawa J, Nakai A, Matsuda K, et al. Reactive oxygen species play an important role in the activation of heat shock factor 1 in ischemic-reperfused heart. Circulation. 1999;99:934-941.
50. Perez NG, Gao WD, Marban E. Novel myofilament Ca + 2-sensitizing property of xanthine oxidase inhibitors. Circ Res. 1998;83:423-430.
51. Yang CS, Tsai PJ, Chou ST, et al. The roles of reactive oxygen species and endogenous opioid peptides in ischemia-induced arrhythmia of isolated rat hearts. Free Radic Biol Med. 1995;18:593-598.
52. Bielefeldt K, Conklin JL. Intestinal motility during hypoxia and reoxygenation in vitro. Dig Dis Sci. 1997;42:878-884.
53. Udassin R, Eimerl D, Schiffman J, et al. Postischemic intestinal motility in rat is inversely correlated to length of ischemia. An in vivo animal model. Dig Dis Sci. 1995;40:1035-1038.
54. Menger MD, Rücker M, Vollmar B. Capillary dysfunction in striated muscle ischemia/reperfusion: on the mechanisms of capillary "no- reflow". Shock. 1997;8:2-7.